nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—CASP3—type 1 diabetes mellitus	0.459	0.611	CbGaD
Minocycline—IL1B—type 1 diabetes mellitus	0.292	0.389	CbGaD
Minocycline—MMP9—tunica intima—type 1 diabetes mellitus	0.00977	0.134	CbGeAlD
Minocycline—CASP3—nerve—type 1 diabetes mellitus	0.00498	0.0685	CbGeAlD
Minocycline—VEGFA—Enalapril—Ramipril—type 1 diabetes mellitus	0.00299	1	CbGdCrCtD
Minocycline—CYCS—islet of Langerhans—type 1 diabetes mellitus	0.00282	0.0387	CbGeAlD
Minocycline—CASP3—islet of Langerhans—type 1 diabetes mellitus	0.00241	0.0332	CbGeAlD
Minocycline—CYCS—retina—type 1 diabetes mellitus	0.00241	0.0331	CbGeAlD
Minocycline—CASP1—cardiovascular system—type 1 diabetes mellitus	0.00212	0.0291	CbGeAlD
Minocycline—CASP1—kidney—type 1 diabetes mellitus	0.00207	0.0285	CbGeAlD
Minocycline—CASP3—retina—type 1 diabetes mellitus	0.00206	0.0284	CbGeAlD
Minocycline—CYCS—cardiovascular system—type 1 diabetes mellitus	0.00204	0.028	CbGeAlD
Minocycline—CYCS—kidney—type 1 diabetes mellitus	0.00199	0.0274	CbGeAlD
Minocycline—CYCS—pancreas—type 1 diabetes mellitus	0.00198	0.0272	CbGeAlD
Minocycline—CASP3—nephron tubule—type 1 diabetes mellitus	0.00194	0.0267	CbGeAlD
Minocycline—IL1B—islet of Langerhans—type 1 diabetes mellitus	0.00193	0.0265	CbGeAlD
Minocycline—VEGFA—islet of Langerhans—type 1 diabetes mellitus	0.0019	0.0261	CbGeAlD
Minocycline—CASP1—lymphoid tissue—type 1 diabetes mellitus	0.00178	0.0245	CbGeAlD
Minocycline—CASP3—cardiovascular system—type 1 diabetes mellitus	0.00175	0.024	CbGeAlD
Minocycline—CYCS—lymphoid tissue—type 1 diabetes mellitus	0.00171	0.0235	CbGeAlD
Minocycline—CASP3—kidney—type 1 diabetes mellitus	0.00171	0.0235	CbGeAlD
Minocycline—CASP3—pancreas—type 1 diabetes mellitus	0.0017	0.0233	CbGeAlD
Minocycline—VEGFA—nephron tubule—type 1 diabetes mellitus	0.00153	0.021	CbGeAlD
Minocycline—CASP3—lymphoid tissue—type 1 diabetes mellitus	0.00147	0.0202	CbGeAlD
Minocycline—IL1B—cardiovascular system—type 1 diabetes mellitus	0.00139	0.0192	CbGeAlD
Minocycline—IL1B—kidney—type 1 diabetes mellitus	0.00136	0.0188	CbGeAlD
Minocycline—IL1B—pancreas—type 1 diabetes mellitus	0.00136	0.0186	CbGeAlD
Minocycline—VEGFA—pancreas—type 1 diabetes mellitus	0.00133	0.0183	CbGeAlD
Minocycline—ALOX5—islet of Langerhans—type 1 diabetes mellitus	0.00127	0.0175	CbGeAlD
Minocycline—SLC22A11—nephron tubule—type 1 diabetes mellitus	0.00123	0.0169	CbGeAlD
Minocycline—IL1B—lymphoid tissue—type 1 diabetes mellitus	0.00117	0.0161	CbGeAlD
Minocycline—MMP9—cardiovascular system—type 1 diabetes mellitus	0.00116	0.016	CbGeAlD
Minocycline—SLC22A6—nephron tubule—type 1 diabetes mellitus	0.00116	0.0159	CbGeAlD
Minocycline—MMP9—kidney—type 1 diabetes mellitus	0.00114	0.0156	CbGeAlD
Minocycline—MMP9—pancreas—type 1 diabetes mellitus	0.00113	0.0155	CbGeAlD
Minocycline—SLC22A11—kidney—type 1 diabetes mellitus	0.00108	0.0148	CbGeAlD
Minocycline—SLC22A7—kidney—type 1 diabetes mellitus	0.00105	0.0145	CbGeAlD
Minocycline—MMP9—lymphoid tissue—type 1 diabetes mellitus	0.000976	0.0134	CbGeAlD
Minocycline—ALOX5—cardiovascular system—type 1 diabetes mellitus	0.000919	0.0126	CbGeAlD
Minocycline—ALOX5—pancreas—type 1 diabetes mellitus	0.000893	0.0123	CbGeAlD
Minocycline—ALOX5—lymphoid tissue—type 1 diabetes mellitus	0.000772	0.0106	CbGeAlD
Minocycline—SLC22A8—nephron tubule—type 1 diabetes mellitus	0.000692	0.00951	CbGeAlD
Minocycline—SLC22A8—kidney—type 1 diabetes mellitus	0.000608	0.00836	CbGeAlD
Minocycline—Methacycline—ALB—type 1 diabetes mellitus	0.000478	0.695	CrCbGaD
Minocycline—Tetracycline—ALB—type 1 diabetes mellitus	0.000209	0.305	CrCbGaD
Minocycline—CASP1—Immune System—HLA-DQA1—type 1 diabetes mellitus	3.94e-05	0.000227	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ITPR3—type 1 diabetes mellitus	3.93e-05	0.000227	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IFNG—type 1 diabetes mellitus	3.91e-05	0.000226	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—PRKCQ—type 1 diabetes mellitus	3.9e-05	0.000225	CbGpPWpGaD
Minocycline—IL1B—Immune System—LGALS3—type 1 diabetes mellitus	3.89e-05	0.000225	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—STAT3—type 1 diabetes mellitus	3.89e-05	0.000224	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TNF—type 1 diabetes mellitus	3.88e-05	0.000224	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TNF—type 1 diabetes mellitus	3.81e-05	0.00022	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—SLC18A2—type 1 diabetes mellitus	3.81e-05	0.00022	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	3.8e-05	0.00022	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—CASP3—type 1 diabetes mellitus	3.8e-05	0.00022	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—TYK2—type 1 diabetes mellitus	3.75e-05	0.000217	CbGpPWpGaD
Minocycline—IL1B—Immune System—ITPR3—type 1 diabetes mellitus	3.71e-05	0.000215	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1B—type 1 diabetes mellitus	3.71e-05	0.000214	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—CASP3—type 1 diabetes mellitus	3.7e-05	0.000214	CbGpPWpGaD
Minocycline—CYCS—Metabolism—HBA1—type 1 diabetes mellitus	3.7e-05	0.000214	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFIH1—type 1 diabetes mellitus	3.69e-05	0.000213	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-DQB1—type 1 diabetes mellitus	3.68e-05	0.000213	CbGpPWpGaD
Minocycline—CYCS—Metabolism—APOC3—type 1 diabetes mellitus	3.68e-05	0.000212	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CDK4—type 1 diabetes mellitus	3.66e-05	0.000212	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IGF1—type 1 diabetes mellitus	3.64e-05	0.00021	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ABCC8—type 1 diabetes mellitus	3.63e-05	0.00021	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GSTT1—type 1 diabetes mellitus	3.61e-05	0.000209	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL6—type 1 diabetes mellitus	3.61e-05	0.000208	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IL6—type 1 diabetes mellitus	3.58e-05	0.000207	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS1—type 1 diabetes mellitus	3.55e-05	0.000205	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD86—type 1 diabetes mellitus	3.55e-05	0.000205	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—EGFR—type 1 diabetes mellitus	3.53e-05	0.000204	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—CP—type 1 diabetes mellitus	3.51e-05	0.000203	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—SLC11A1—type 1 diabetes mellitus	3.48e-05	0.000201	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD40LG—type 1 diabetes mellitus	3.48e-05	0.000201	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL2—type 1 diabetes mellitus	3.48e-05	0.000201	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—ALB—type 1 diabetes mellitus	3.45e-05	0.000199	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD8A—type 1 diabetes mellitus	3.44e-05	0.000199	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CD4—type 1 diabetes mellitus	3.39e-05	0.000196	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—PRKCQ—type 1 diabetes mellitus	3.39e-05	0.000196	CbGpPWpGaD
Minocycline—IL1B—Immune System—PTPN2—type 1 diabetes mellitus	3.37e-05	0.000195	CbGpPWpGaD
Minocycline—IL1B—Immune System—B2M—type 1 diabetes mellitus	3.34e-05	0.000193	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—PRKCQ—type 1 diabetes mellitus	3.32e-05	0.000192	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-B—type 1 diabetes mellitus	3.31e-05	0.000191	CbGpPWpGaD
Minocycline—IL1B—Myometrial Relaxation and Contraction Pathways—IL6—type 1 diabetes mellitus	3.28e-05	0.000189	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL6—type 1 diabetes mellitus	3.27e-05	0.000189	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL6—type 1 diabetes mellitus	3.26e-05	0.000189	CbGpPWpGaD
Minocycline—SLC22A11—SLC-mediated transmembrane transport—ALB—type 1 diabetes mellitus	3.23e-05	0.000187	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—VAV1—type 1 diabetes mellitus	3.23e-05	0.000186	CbGpPWpGaD
Minocycline—CASP1—Immune System—ERBB3—type 1 diabetes mellitus	3.2e-05	0.000185	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—SLC18A2—type 1 diabetes mellitus	3.18e-05	0.000184	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—GAL—type 1 diabetes mellitus	3.18e-05	0.000184	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—STAT3—type 1 diabetes mellitus	3.18e-05	0.000184	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	3.17e-05	0.000183	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CASP3—type 1 diabetes mellitus	3.15e-05	0.000182	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL20—type 1 diabetes mellitus	3.14e-05	0.000182	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL11—type 1 diabetes mellitus	3.14e-05	0.000182	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL6—type 1 diabetes mellitus	3.13e-05	0.000181	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL2RA—type 1 diabetes mellitus	3.1e-05	0.000179	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-A—type 1 diabetes mellitus	3.06e-05	0.000177	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CHRM2—type 1 diabetes mellitus	2.96e-05	0.000171	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DPB1—type 1 diabetes mellitus	2.95e-05	0.00017	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—IL6—type 1 diabetes mellitus	2.94e-05	0.00017	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL6—type 1 diabetes mellitus	2.93e-05	0.000169	CbGpPWpGaD
Minocycline—SLC22A7—SLC-mediated transmembrane transport—ALB—type 1 diabetes mellitus	2.93e-05	0.000169	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—CP—type 1 diabetes mellitus	2.93e-05	0.000169	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—STAT3—type 1 diabetes mellitus	2.93e-05	0.000169	CbGpPWpGaD
Minocycline—CASP1—Immune System—CRP—type 1 diabetes mellitus	2.92e-05	0.000169	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IGF2—type 1 diabetes mellitus	2.92e-05	0.000169	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—SLC11A1—type 1 diabetes mellitus	2.9e-05	0.000168	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—EGFR—type 1 diabetes mellitus	2.9e-05	0.000168	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-E—type 1 diabetes mellitus	2.9e-05	0.000168	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—EGFR—type 1 diabetes mellitus	2.89e-05	0.000167	CbGpPWpGaD
Minocycline—CYCS—Metabolism—GCG—type 1 diabetes mellitus	2.88e-05	0.000166	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—KCNJ11—type 1 diabetes mellitus	2.87e-05	0.000166	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—TYK2—type 1 diabetes mellitus	2.85e-05	0.000165	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-DRB1—type 1 diabetes mellitus	2.8e-05	0.000162	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—CASP3—type 1 diabetes mellitus	2.8e-05	0.000162	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—IL2—type 1 diabetes mellitus	2.8e-05	0.000162	CbGpPWpGaD
Minocycline—IL1B—Immune System—CTLA4—type 1 diabetes mellitus	2.79e-05	0.000161	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—IL6—type 1 diabetes mellitus	2.77e-05	0.00016	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—IL6—type 1 diabetes mellitus	2.71e-05	0.000157	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—type 1 diabetes mellitus	2.69e-05	0.000156	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD79A—type 1 diabetes mellitus	2.67e-05	0.000154	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ITPR3—type 1 diabetes mellitus	2.65e-05	0.000153	CbGpPWpGaD
Minocycline—IL1B—Immune System—PRKCQ—type 1 diabetes mellitus	2.62e-05	0.000151	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD80—type 1 diabetes mellitus	2.59e-05	0.000149	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CDK4—type 1 diabetes mellitus	2.56e-05	0.000148	CbGpPWpGaD
Minocycline—IL1B—Immune System—VAV1—type 1 diabetes mellitus	2.54e-05	0.000147	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SH2B3—type 1 diabetes mellitus	2.5e-05	0.000144	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—APOC3—type 1 diabetes mellitus	2.48e-05	0.000143	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IAPP—type 1 diabetes mellitus	2.48e-05	0.000143	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—TYK2—type 1 diabetes mellitus	2.48e-05	0.000143	CbGpPWpGaD
Minocycline—SLC22A8—SLC-mediated transmembrane transport—ALB—type 1 diabetes mellitus	2.46e-05	0.000142	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DQA1—type 1 diabetes mellitus	2.46e-05	0.000142	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IL2RA—type 1 diabetes mellitus	2.46e-05	0.000142	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CAT—type 1 diabetes mellitus	2.44e-05	0.000141	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ITPR3—type 1 diabetes mellitus	2.42e-05	0.00014	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—EGFR—type 1 diabetes mellitus	2.41e-05	0.000139	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—type 1 diabetes mellitus	2.4e-05	0.000139	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—EGFR—type 1 diabetes mellitus	2.39e-05	0.000138	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DQB1—type 1 diabetes mellitus	2.3e-05	0.000133	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	2.29e-05	0.000132	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—HBA1—type 1 diabetes mellitus	2.28e-05	0.000132	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—INS—type 1 diabetes mellitus	2.28e-05	0.000132	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—APOC3—type 1 diabetes mellitus	2.27e-05	0.000131	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GSTT1—type 1 diabetes mellitus	2.23e-05	0.000129	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—IL6—type 1 diabetes mellitus	2.22e-05	0.000128	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CDK4—type 1 diabetes mellitus	2.22e-05	0.000128	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD86—type 1 diabetes mellitus	2.22e-05	0.000128	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GAL—type 1 diabetes mellitus	2.21e-05	0.000127	CbGpPWpGaD
Minocycline—CASP1—Immune System—TYK2—type 1 diabetes mellitus	2.18e-05	0.000126	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL11—type 1 diabetes mellitus	2.18e-05	0.000126	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL20—type 1 diabetes mellitus	2.18e-05	0.000126	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SST—type 1 diabetes mellitus	2.18e-05	0.000126	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD40LG—type 1 diabetes mellitus	2.17e-05	0.000126	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL6—type 1 diabetes mellitus	2.17e-05	0.000126	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ADRB1—type 1 diabetes mellitus	2.17e-05	0.000125	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD8A—type 1 diabetes mellitus	2.15e-05	0.000124	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS2—type 1 diabetes mellitus	2.12e-05	0.000122	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-B—type 1 diabetes mellitus	2.07e-05	0.000119	CbGpPWpGaD
Minocycline—SLC22A6—SLC-mediated transmembrane transport—ALB—type 1 diabetes mellitus	2.06e-05	0.000119	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CHRM2—type 1 diabetes mellitus	2.05e-05	0.000119	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	2.05e-05	0.000119	CbGpPWpGaD
Minocycline—CASP1—Immune System—IFNG—type 1 diabetes mellitus	2.04e-05	0.000118	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL6—type 1 diabetes mellitus	2.04e-05	0.000118	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—STAT3—type 1 diabetes mellitus	2.04e-05	0.000118	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TYK2—type 1 diabetes mellitus	2.04e-05	0.000118	CbGpPWpGaD
Minocycline—IL1B—Immune System—ERBB3—type 1 diabetes mellitus	2e-05	0.000115	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—INS—type 1 diabetes mellitus	1.98e-05	0.000114	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD4—type 1 diabetes mellitus	1.98e-05	0.000114	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—GCG—type 1 diabetes mellitus	1.94e-05	0.000112	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL2RA—type 1 diabetes mellitus	1.94e-05	0.000112	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GAL—type 1 diabetes mellitus	1.92e-05	0.000111	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-A—type 1 diabetes mellitus	1.92e-05	0.000111	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL20—type 1 diabetes mellitus	1.89e-05	0.000109	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL11—type 1 diabetes mellitus	1.89e-05	0.000109	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IGF1—type 1 diabetes mellitus	1.88e-05	0.000108	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	1.87e-05	0.000108	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ITPR3—type 1 diabetes mellitus	1.84e-05	0.000106	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—IL6—type 1 diabetes mellitus	1.83e-05	0.000106	CbGpPWpGaD
Minocycline—IL1B—Immune System—CRP—type 1 diabetes mellitus	1.83e-05	0.000106	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1B—type 1 diabetes mellitus	1.82e-05	0.000105	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL2—type 1 diabetes mellitus	1.82e-05	0.000105	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—VAV1—type 1 diabetes mellitus	1.82e-05	0.000105	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—EGFR—type 1 diabetes mellitus	1.81e-05	0.000105	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL10—type 1 diabetes mellitus	1.81e-05	0.000105	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CHRM2—type 1 diabetes mellitus	1.78e-05	0.000103	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—ALB—type 1 diabetes mellitus	1.78e-05	0.000103	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—GCG—type 1 diabetes mellitus	1.77e-05	0.000102	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TYK2—type 1 diabetes mellitus	1.77e-05	0.000102	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-DRB1—type 1 diabetes mellitus	1.75e-05	0.000101	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SH2B3—type 1 diabetes mellitus	1.73e-05	0.0001	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IAPP—type 1 diabetes mellitus	1.72e-05	9.95e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—APOC3—type 1 diabetes mellitus	1.72e-05	9.95e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NOS3—type 1 diabetes mellitus	1.7e-05	9.83e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF2—type 1 diabetes mellitus	1.64e-05	9.5e-05	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.64e-05	9.49e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—INS—type 1 diabetes mellitus	1.62e-05	9.34e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD80—type 1 diabetes mellitus	1.62e-05	9.34e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ITPR3—type 1 diabetes mellitus	1.6e-05	9.24e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CD86—type 1 diabetes mellitus	1.58e-05	9.15e-05	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—EGFR—type 1 diabetes mellitus	1.58e-05	9.1e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—STAT3—type 1 diabetes mellitus	1.53e-05	8.83e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SST—type 1 diabetes mellitus	1.51e-05	8.74e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ADRB1—type 1 diabetes mellitus	1.51e-05	8.7e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SH2B3—type 1 diabetes mellitus	1.5e-05	8.69e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.5e-05	8.68e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CAT—type 1 diabetes mellitus	1.5e-05	8.67e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—APOC3—type 1 diabetes mellitus	1.5e-05	8.64e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IAPP—type 1 diabetes mellitus	1.5e-05	8.64e-05	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.49e-05	8.61e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—ALB—type 1 diabetes mellitus	1.48e-05	8.57e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—IL2—type 1 diabetes mellitus	1.44e-05	8.33e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.43e-05	8.25e-05	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL6—type 1 diabetes mellitus	1.43e-05	8.24e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—STAT3—type 1 diabetes mellitus	1.43e-05	8.23e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—NOS3—type 1 diabetes mellitus	1.42e-05	8.19e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.4e-05	8.11e-05	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—IL6—type 1 diabetes mellitus	1.39e-05	8.06e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—EGFR—type 1 diabetes mellitus	1.39e-05	8.03e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.38e-05	7.99e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—TYK2—type 1 diabetes mellitus	1.36e-05	7.88e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—GCG—type 1 diabetes mellitus	1.35e-05	7.79e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SST—type 1 diabetes mellitus	1.31e-05	7.59e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ADRB1—type 1 diabetes mellitus	1.31e-05	7.55e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	1.3e-05	7.5e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EGFR—type 1 diabetes mellitus	1.3e-05	7.48e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IFNG—type 1 diabetes mellitus	1.28e-05	7.38e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—VAV1—type 1 diabetes mellitus	1.26e-05	7.28e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL10—type 1 diabetes mellitus	1.26e-05	7.26e-05	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.25e-05	7.23e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—STAT3—type 1 diabetes mellitus	1.24e-05	7.15e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD4—type 1 diabetes mellitus	1.23e-05	7.13e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—type 1 diabetes mellitus	1.23e-05	7.12e-05	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—IL6—type 1 diabetes mellitus	1.21e-05	6.99e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—GCG—type 1 diabetes mellitus	1.17e-05	6.76e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CD80—type 1 diabetes mellitus	1.15e-05	6.67e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF2—type 1 diabetes mellitus	1.14e-05	6.59e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL2—type 1 diabetes mellitus	1.14e-05	6.56e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	1.13e-05	6.51e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EGFR—type 1 diabetes mellitus	1.12e-05	6.49e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CD86—type 1 diabetes mellitus	1.1e-05	6.35e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—VAV1—type 1 diabetes mellitus	1.09e-05	6.32e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—INS—type 1 diabetes mellitus	1.09e-05	6.3e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL10—type 1 diabetes mellitus	1.09e-05	6.3e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TNF—type 1 diabetes mellitus	1.07e-05	6.19e-05	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL6—type 1 diabetes mellitus	1.07e-05	6.17e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.06e-05	6.1e-05	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.05e-05	6.04e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.04e-05	6.02e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—INS—type 1 diabetes mellitus	9.97e-06	5.76e-05	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—IL6—type 1 diabetes mellitus	9.95e-06	5.75e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ERBB3—type 1 diabetes mellitus	9.91e-06	5.72e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF2—type 1 diabetes mellitus	9.91e-06	5.72e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TYK2—type 1 diabetes mellitus	9.75e-06	5.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCR5—type 1 diabetes mellitus	9.75e-06	5.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL2RA—type 1 diabetes mellitus	9.61e-06	5.55e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NOS3—type 1 diabetes mellitus	9.57e-06	5.53e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—STAT3—type 1 diabetes mellitus	9.56e-06	5.52e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CD86—type 1 diabetes mellitus	9.54e-06	5.51e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—ALB—type 1 diabetes mellitus	9.14e-06	5.28e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—E2F1—type 1 diabetes mellitus	9.05e-06	5.23e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—NOS3—type 1 diabetes mellitus	8.74e-06	5.05e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—EGFR—type 1 diabetes mellitus	8.69e-06	5.02e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—IL6—type 1 diabetes mellitus	8.64e-06	4.99e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ERBB3—type 1 diabetes mellitus	8.6e-06	4.97e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCR5—type 1 diabetes mellitus	8.46e-06	4.89e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL2RA—type 1 diabetes mellitus	8.34e-06	4.82e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL2—type 1 diabetes mellitus	8.11e-06	4.69e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CD80—type 1 diabetes mellitus	8.02e-06	4.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—INS—type 1 diabetes mellitus	7.58e-06	4.38e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1—type 1 diabetes mellitus	7.33e-06	4.23e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CD80—type 1 diabetes mellitus	6.96e-06	4.02e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—STAT3—type 1 diabetes mellitus	6.83e-06	3.94e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TYK2—type 1 diabetes mellitus	6.77e-06	3.91e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL6—type 1 diabetes mellitus	6.68e-06	3.86e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NOS3—type 1 diabetes mellitus	6.64e-06	3.84e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—INS—type 1 diabetes mellitus	6.58e-06	3.8e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1—type 1 diabetes mellitus	6.36e-06	3.67e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EGFR—type 1 diabetes mellitus	6.2e-06	3.58e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TYK2—type 1 diabetes mellitus	5.88e-06	3.39e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NOS3—type 1 diabetes mellitus	5.77e-06	3.33e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CASP3—type 1 diabetes mellitus	5.64e-06	3.26e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL2—type 1 diabetes mellitus	5.63e-06	3.25e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CASP3—type 1 diabetes mellitus	4.9e-06	2.83e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL2—type 1 diabetes mellitus	4.89e-06	2.82e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IL6—type 1 diabetes mellitus	4.77e-06	2.75e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—STAT3—type 1 diabetes mellitus	4.74e-06	2.74e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EGFR—type 1 diabetes mellitus	4.31e-06	2.49e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—STAT3—type 1 diabetes mellitus	4.11e-06	2.38e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EGFR—type 1 diabetes mellitus	3.74e-06	2.16e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IL6—type 1 diabetes mellitus	3.31e-06	1.91e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IL6—type 1 diabetes mellitus	2.87e-06	1.66e-05	CbGpPWpGaD
